1. Chauhan AS, Prinja S, Ghoshal S, Verma R. Cost-effectiveness of treating head and neck cancer using intensity-modulated radiation therapy: implications for cancer control program in India. Int J Technol Assess Health Care. 2020 Sep 23:1-8. doi: 10.1017/S0266462320000677
2. Chauhan AS, Prinja S, Srinivasan R, Rai B, Malliga JS, Jyani G, Gupta N, Ghoshal S. Cost effectiveness of strategies for cervical cancer prevention in India. PLoS One. 2020 Sep 1;15(9):e0238291. doi: 10.1371/journal.pone.0238291. PMID: 32870941; PMCID: PMC7462298.
3. Jyani G, Prinja S, Ambekar A, Bahuguna P, Kumar R. Health impact and economic burden of alcohol consumption in India. International Journal of Drug Policy. 2019 Jul 1;69:34-42.
4. Chugh Y, Dhiman RK, Premkumar M, Prinja S, Singh Grover G, Bahuguna P. Real-world cost-effectiveness of pan-genotypic Sofosbuvir-Velpatasvir combination versus genotype dependent directly acting anti-viral drugs for treatment of hepatitis C patients in the universal coverage scheme of Punjab state in India. PLoS One. 2019 Aug 29;14(8):e0221769. doi: 10.1371/journal.pone.0221769. PMID: 31465503; PMCID: PMC6715223.
5. Prinja S, Chauhan AS, Bahuguna P, Selvaraj S, Muraleedharan VR, Sundararaman T. Cost of Delivering Secondary Healthcare Through the Public Sector in India. Pharmacoecon Open. 2019 Aug 29. doi: 10.1007/s41669-019-00176-9. [Epub ahead of print]
6. Prinja S, Bahuguna P, Gupta A, Nimesh R, Gupta M, Thakur JS.
Cost effectiveness of mHealth intervention by community health workers for reducingmaternal and newborn mortality in rural Uttar Pradesh, India.
Cost Eff ResourAlloc. 2018 Jun 25;16:25. doi: 10.1186/s12962-018-0110-2.
7. Gupta N, Verma RK, Prinja S, Dhiman RK. Cost-effectiveness of Sorafenib for Treatment of Advanced Hepatocellular Carcinoma in India.
Journal of Clinical and Experimental Hepatology. 2018 Oct 31.
8. John M J, Jyani G, Jindal A, Mashon RS, Mathew A, Kakkar S, Bahuguna P, Prinja S. Cost Effectiveness of Hematopoietic Stem Cell Transplantation Compared with Transfusion Chelation for Treatment of Thalassemia Major.
Biol Blood Marrow Transplant. 2018 Oct;24(10):2119-2126. doi: 10.1016/j.bbmt.2018.04.005.
9. Prinja S, Bahuguna P, Faujdar DS, Jyani G, Srinivasan R, Ghoshal S, Suri V,Singh MP, Kumar R. Cost-effectiveness of human papillomavirus vaccination for adolescent girls in Punjab state: Implications for India's universal immunization program.
Cancer. 2017 Sep 1;123(17):3253-3260. doi: 10.1002/cncr.30734.
10. Prinja S, Kaur G, Malhotra P, Jyani G, Ramachandran R, Bahuguna P, Varma S.Cost-Effectiveness of Autologous Stem Cell Treatment as Compared to Conventional Chemotherapy for Treatment of Multiple Myeloma in India.
Indian J Hematol Blood Transfus. 2017 Mar;33(1):31-40. doi: 10.1007/s12288-017-0776-1.
11. Prinja S, Bahuguna P, Mohan P, Mazumder S, Taneja S, Bhandari N, van denHombergh H, Kumar R.
Cost Effectiveness of Implementing Integrated Management of Neonatal and Childhood Illnesses Program in District Faridabad, India. PLoS One.
2016 Jan 4;11(1):e0145043. doi: 10.1371/journal.pone.0145043.
12. Dhivya PS, Swathy G, Pal S. Pharmacoeconomics of antihypertensive drugs prescribed in a multispecialty hospital in South India.
Asian J Pharm. 2014;8(3):178–82.
13. Eaton JW, Menzies NA, Stover J, Cambiano V, Chindelevitch L, Cori A, et al. Health benefits, costs, and cost-effectiveness of earlier
eligibility for adult antiretroviral therapy and expanded treatment coverage: A combined analysis of 12 mathematical models. Lancet Glob Heal. 2014;2(1):e23–34.
14. Rheingans R, Anderson JD, Anderson B, Chakraborty P, Atherly D, Pindolia D. Estimated impact and cost-effectiveness of rotavirus
vaccination in India: effects of geographic and economic disparities. Vaccine [Internet]. 2014;32Suppl 1:A140–50.
15. Singh K. Economic evaluation of Japanese encephalitis vaccination programme in Uttar Pradesh, India : a cost-benefit study.
J Vector Borne Dis. 2014;51(1):47–52.
16. Vassall A, Pickles M, Chandrashekar S, Boily M-C, Shetty G, Guinness L, et al. Cost-effectiveness of HIV prevention for high-risk
groups at scale: an economic evaluation of the Avahan programme in south India. Lancet Glob Heal [Internet]. 2014;2(9):e531–40.
17. Vijendra R, Kumar A, Girish K, Harsha R, Reddy V, Lakshmi P. Cost-effectiveness analysis of baclofen and chlordiazepoxide in uncomplicated
alcohol-withdrawal syndrome. Indian J Pharmacol.2014;46(4):372.
18. Bindoria SV, Devkar R, Gupta I, Ranebennur V, Saggurti N, Ramesh S, et al. Development and pilot testing of HIV screening program integration
within public/primary health centers providing antenatal care services in Maharashtra, India. BMC Res Notes. 2014;7(1):177.
19. Vassall A, Chandrashekar S, Pickles M, Beattie T, Shetty G, Bhattacharjee P, et al. Community mobilisation and empowerment
interventions as part of HIV prevention for female sex workers in Southern India: A cost-effectiveness analysis. 2014;9(10):e110562.
20. Aggarwal K, Khandpur S, Khanna N, Sharma VK, Pandav CS. Comparison of clinical and cost-effectiveness of psoralen? ultraviolet A
versus psoralen? sunlight in the treatment of chronic plaque psoriasis in a developing economy. Int J Dermatol. 2013;52(4):478–85.
21. Brown HS, Stigler M, Perry C, Dhavan P, Arora M, Reddy KS. The cost-effectiveness of a school-based smoking prevention program in
India. Health Promot Int. 2013;28(2):178–86.
22. Clark AD, Griffiths UK, Abbas SS, Rao KD, Privor-Dumm L, Hajjeh R, et al. Impact and cost-effectiveness of haemophilusinfluenzae type
b conjugate vaccination in india. J Pediatr [Internet]. 2013;163(1):S60–72.
23. Gupta M, Prinja S, Kumar R, Kaur M. Cost-effectiveness of Haemophilusinfluenzae type b (Hib) vaccine introduction in the universal
immunization schedule in Haryana State, India. Health Policy Plan. 2013;28(1):51–61.
24. Marseille E, Lohse N, Jiwani A, Hod M, Seshiah V, Yajnik CS, et al. The cost-effectiveness of gestational diabetes screening
including prevention of type 2 diabetes: application of a new model in India and Israel. J Matern Fetal Neonatal Med.
25. Rachapelle S, Legood R, Alavi Y, Lindfield R, Sharma T, Kuper H, et al. The cost-utility of telemedicine to screen for
diabetic retinopathy in india. Ophthalmology [Internet]. 2013;120(3):566–73.
26. Sriram S, Aiswaria V, Cijo A, Mohankumar T. Antibiotic sensitivity pattern and cost-effectiveness analysis of antibiotic therapy
in an Indian tertiary care teaching hospital. J Res Pharm Pract. 2013;2(2):70.
27. Thaker S, Mehta D, Shah H, Dave J, Kikani K. A comparative study to evaluate efficacy, safety and cost-effectiveness between
Whitfield′s ointment + oral fluconazole versus topical 1 % butenafine in tinea infections of skin. Indian J Pharmacol.
28. Thaker S, Mehta D, Shah H, Dave J, Mundhava S. A comparative randomized open label study to evaluate efficacy, safety and cost
effectiveness between topical 2 % sertaconazole and topical 1 % butenafine in tinea infections of skin.Indian J Dermatol.
29. Van’tHoog AH, Cobelens F, Vassall A, Van Kampen S, Dorman SE, Alland D, et al. Optimal triage test characteristics to improve the
cost-effectiveness of the Xpert MTB/RIF assay for TB diagnosis: A decision analysis. PLoS One. 2013;8(12):e82786.
30. Venkatesh KK, Becker JE, Kumarasamy N, Nakamura YM, Mayer KH, Losina E, et al. Clinical Impact and Cost-Effectiveness of Expanded
Voluntary HIV Testing in India. PLoS One. 2013;8(5):e64604.
31. Walensky RP, Ross EL, Kumarasamy N, Wood R, Noubary F, Paltiel AD, et al. Cost-effectiveness of HIV treatment as prevention in
serodiscordant couples. N Engl J Med. 2013;369:1715–25.
32. Verguet S, Murphy S, Anderson B, Johansson KA, Glass R, Rheingans R. Public finance of rotavirus vaccination in India and Ethiopia:
An extended cost-effectiveness analysis. Vaccine [Internet]. 2013;31(42):4902–10.
33. Buttorff C, Hock RS, Weiss HA, Naik S, Araya R, Kirkwood BR, et al. Economic evaluation of a task-shifting intervention for common
mental disorders in India. Bull World Health Organ. 2012;90(11):813–21.
34. Pandav C. Economic evaluation of iodine deficiency disorder control program in Sikkim: a cost effectiveness study. Indian J Public
35. Lee BY, Bacon KM, Shah M, Kitchen SB, Connor DL, Slayton RB.The economic value of a visceral leishmaniasis vaccine in Bihar State,
India. Am J Trop Med Hyg. 2012;86(3):417–25.
36. Pho MT, Swaminathan S, Kumarasamy N, Losina E, Ponnuraja C, Uhler LM, et al. The cost-effectiveness of tuberculosis preventive
therapy for HIV-infected individuals in southern India: a trial-based analysis. PLoS One. 2012;7(4):e36001.
37. Reid S. Estimating the burden of disease from unsafe injections in India: a cost-benefit assessment of the auto-disable syringe in
a country with low blood-borne virus prevalence. Indian J Community Med. 2012;37(2):89–94.
38. Burke MJ, Shenton RC, Taylor MJ. The economics of screening infants at risk of hearing impairment: an international analysis.
Int J Pediatr Otorhinolaryngol. 2012;76(2):212–8.
39. Pandav CS. Economic evaluation of iodine deficiency disorder control program in Sikkim: a cost effectiveness study. Indian J Public
40. Alexander A, John KR, Jayaraman T, Oommen A, VenkataRaghava M, Dorny P, et al. Economic implications of three strategies for the
control of taeniasis. Trop Med Int Health. 2011;16(11):1410–6.
41. Donaldson EA, Waters HR, Arora M, Varghese B, Dave P, Modi B. A cost-effectiveness analysis of India’s 2008 prohibition of smoking in
public places in Gujarat.Int J Environ Res Public Health. 2011;8(5):1271–86.
42. Dowdy DW, Steingart KR, Pai M. Serological testing versus other strategies for diagnosis of active tuberculosis in india: a
cost-effectiveness analysis. PLoS Med. 2011;8(8):e1001074.
43. Dranitsaris G, Truter I, Lubbe MS, Sriramanakoppa NN, Mendonca VM, Mahagaonkar SB. Improving patient access to cancer drugs in India:
Using economic modeling to estimate a more affordable drug cost based on measures of societal value. Int J Technol Assess Health Care.
44. Esposito DH, Tate JE, Kang G, Parashar UD. Projected impact and cost-effectiveness of a rotavirus vaccination program in India,
2008.Clin Infect Dis. 2011;52(2):171–7.
45. Goodchild M, Sahu S, Wares F, Dewan P, Shukla RS, Chauhan LS, et al.A cost-benefit analysis of scaling up tuberculosis control in
India.Int J Tuberc Lung Dis. 2011;15(3):358–62.
46. Guerriero C, Cairns J, Perel P, Shakur H, Roberts I. Cost-effectiveness analysis of administering tranexamic acid to bleeding trauma
patients using evidence from the crash-2 trial. PLoS One. 2011;6(5):e18987.
47. Lohse N, Marseille E, Kahn JG. Development of a model to assess the cost-effectiveness of gestational diabetes mellitus screening and
lifestyle change for the prevention of type 2 diabetes mellitus. Int J GynecolObstet [Internet]. 2011;115 Suppl:S20–5.
48. Massad E, Behrens BC, Coutinho F a B, Behrens RH. Cost risk benefit analysis to support chemoprophylaxis policy for travellers to
malaria endemic countries. Malar J [Internet]. 2011;10(1):130.
49. Prinja S, Bahuguna P, Rudra S, Gupta I, Kaur M, Mehendale SM, et al. Cost effectiveness of targeted HIV prevention interventions
for female sex workers in India. Sex Transm Infect. 2011;87(4):354–61.
50. Singh SP, Hirve S, Huda MM, Banjara MR, Kumar N, Mondal D. Options for active case detection of visceral leishmaniasis in endemic
districts of India, Nepal and Bangladesh, comparing yield, feasibility and costs. PLoSNegl Trop Dis. 2011;5(2):e960.
51. Bender MA, Kumarasamy N, Mayer KH, Wang B, Walensky RP, Flanigan T, et al. Cost-effectiveness of tenofovir as first-line
antiretroviral therapy in India. Clin Infect Dis. 2010;50(3):416–25.
52. Cecchini M, Sassi F, Lauer JA, Lee YY, Guajardo-Barron V, Chisholm D. Tackling of unhealthy diets, physical inactivity, and obesity:
health effects and cost-effectiveness. Lancet. 2010;376(9754):1775–84
53. Chow J, Klein EY, Laxminarayan R. Cost-effectiveness of “golden mustard” for treating vitamin a deficiency in India.PLoS One.
54. Dandona L, Kumar SGP, Kumar GA, Dandona R. Cost-effectiveness of HIV prevention interventions in Andhra Pradesh state of India.
BMC Health Serv Res. 2010;10:117.
55. Goldie SJ, Sweet S, Carvalho N, Natchu UCM, Hu D. Alternative strategies to reduce maternal mortality in India: a cost-effectiveness
analysis. PLoS Med. 2010;7(4):e1000264.
56. Jothi R, Ismail AM, Senthamarai R, Pal S. A comparative study on the efficacy, safety, and cost-effectiveness of bimatoprost/timolol
and dorzolamide/timolol combinations in glaucoma patients.Indian J Pharmacol. 2010;42(6):362–5.
57. Mahajan R, Gupta A, Gupta RS, Gupta K. Efficacy, safety and cost-effectiveness of insulin sensitizers as add-on therapy in metabolic
syndrome in patients with secondary sulfonylurea failure: a comparative study. J PharmacolPharmacother. 2010;1(2):82–6.
58. Meheus F, Balasegaram M, Olliaro P, Sundar S, Rijal S, Faiz MA, et al. Cost-effectiveness analysis of combination therapies for
visceral leishmaniasis in the Indian subcontinent. PLoSNegl Trop Dis. 2010;4(9).
59. Mukherjee K. Cost-effectiveness of childbirth strategies for prevention of mother-to-child transmission of HIV among mothers
receiving nevirapine in India. Indian J Community Med. 2010;35(1):29–33.
60. Schulman-Marcus J, Prabhakaran D, Gaziano TA. Pre-hospital ECG for acute coronary syndrome in urban India: a cost-effectiveness
analysis. BMC CardiovascDisord. 2010;10:13.
61. Sutherland T, Meyer C, Bishai DM, Geller S, Miller S. Community-based distribution of misoprostol for treatment or prevention of
postpartum hemorrhage: Cost-effectiveness, mortality, and morbidity reduction analysis. Int J GynecolObstet [Internet].
62. Uhler LM, Kumarasamy N, Mayer KH, Saxena A, Losina E, Muniyandi M, et al. Cost-effectiveness of HIV testing referral strategies
among tuberculosis patients in India. PLoS One. 2010;5(9):1–9.
63. Bachewar NP, Thawani VR, Mali SN, Gharpure KJ, Shingade VP, Dakhale GN.Comparison of safety, efficacy, and cost effectiveness of
benzyl benzoate, permethrin, and ivermectin in patients of scabies.Indian J Pharmacol. 2009;41(1):9–14.
64. Dabral M. Cost-effectiveness of supplementary immunization for measles in India.Indian Pediatr. 2009;46(3):957–62.
65. Frick KD, Riva-Clement L, Shankar MB. Screening for refractive error and fitting with spectacles in rural and urban India:
cost-effectiveness. Ophthalmic Epidemiol. 2009;16(6):378–87.
66. Jeuland M, Cook J, Poulos C, Clemens J, Whittington D. Cost-effectiveness of new-generation oral cholera vaccines: a multisite
analysis. Value Health. 2009;12(6):899–908.
67. Lubell Y, Yeung S, Dondorp AM, Day NP, Nosten F, Tjitra E, et al. Cost-effectiveness of artesunate for the treatment of severe malaria.
Trop Med Int Heal. 2009;14(3):332–7.
68. Rob B, Vinod JA, Monica P, Balraj A, Job A, Norman G, et al. Costs and health effects of screening and delivery of hearing aids in
Tamil Nadu, India: an observational study. BMC Public Health. 2009;9:135.
69. Rose J, Hawthorn RL, Watts B, Singer ME. Public health impact and cost effectiveness of mass vaccination with live attenuated
human rotavirus vaccine (RIX4414) in India: model based analysis. BMJ. 2009;339:b3653.
70. Subramanian S, Sankaranarayanan R, Bapat B, Somanathan T, Thomas G, Mathew B, et al. Cost-effectiveness of oral cancer screening:
Results from a cluster randomized controlled trial in India. Bull World Health Organ. 2009;87(3):200–6.
71. Sutherland T, Bishai DM. Cost-effectiveness of misoprostol and prenatal iron supplementation as maternal mortality interventions
in home births in rural India.Int J GynecolObstet [Internet]. 2009;104(3):189–93.
72. Pantoja A, Lönnroth K, Lal SS, Chauhan LS.Economic evaluation of public-private mix for tuberculosis care and control, India.
Part II. Cost and cost-effectiveness.Int J Tuberc Lung Dis. 2009;13(6):705–12.
73. Olliaro P, Darley S, Laxminarayan R, Sundar S. Cost-effectiveness projections of single and combination therapies for visceral
leishmaniasis in Bihar. India. Trop Med Int Heal. 2009;14(8):918–25.
74. Bhagia L J, Sadhu HG. Cost-benefit analysis of installing
dust control devices in the agate industry, Khambhat (Gujarat). Indian J Occup Environ Med. 2008;12(3):128–31.
75. Goldie SJ, O’Shea M, Campos NG, Diaz M, Sweet S, Kim SY. Health and economic outcomes of HPV 16,18 vaccination in 72 GAVI-eligible
countries. Vaccine. 2008;26(32):4080–93.
76. Cook J, Jeuland M, Whittington D, Poulos C, Clemens J, Sur D, et al. The cost-effectiveness of typhoid Vi vaccination programs:
calculations for four urban sites in four Asian countries. Vaccine. 2008;26(50):6305–16.
77. Kochhar P, Suvarna V, Duttagupta S, Sarkar S. Cost-effectiveness study comparing cefoperazone-sulbactam to a three-drug combination
for treating intraabdominal infections in an Indian health-care setting. Value Health. 2008;11(Suppl 1):S33–8.
78. Okonkwo QL, Draisma G, Der Kinderen A, Brown ML, De Koning HJ. Breast cancer screening policies in developing countries:
a cost-effectiveness analysis for India. J Natl Cancer Inst. 2008;100(18):1290–300.74.
79. Paul SB, Sreenivas V, Gulati MS, Madan K, Gupta AK, Mukhopadhyay S, et al. Economic evaluation of a surveillance program of
hepatocellular carcinoma (HCC) in India.Hepatol Int. 2008;2(2):231–6.
80. Suraratdecha C, Ramana CV, Kaipilyawar S, Krishnamurthy J, Sivalenka S, Ambatipudi N, et al. Cost and effectiveness analysis of
immunization service delivery support in Andhra Pradesh, India. Bull World Health Organ. 2008;86(3):221–8.
81. Diaz M, Kim JJ, Albero G, de Sanjosé S, Clifford G, Bosch FX, et al. Health and economic impact of HPV 16 and 18 vaccination and
cervical cancer screening in India. Br J Cancer. 2008;99(2):230–8.
82. Ferroussier O, Kumar MKA, Dewan PK, Nair PKJ, Sahu S, Wares DF, et al. Cost and cost-effectiveness of a public-private mix project
in Kannur District Kerala, India, 2001–2002. Int J Tuberc Lung Dis. 2007;11(7):755–61. 45.
83. Freedberg KA, Kumarasamy N, Losina E, Cecelia AJ, Scott CA, Divi N, et al. Clinical impact and cost effectivceness of antiretroviral
therapy in India: starting criteria and second line therapy. AIDS. 2007;21(Suppl 4):S117–28.
84. Fung IC-H, Guinness L, Vickerman P, Watts C, Vannela G, Vadhvana J, et al. Modelling the impact and cost-effectiveness of the HIV
intervention programme amongst commercial sex workers in Ahmedabad, Gujarat, India. BMC Public Health. 2007;7:195.
85. Ramachandran A, Snehalatha C, Yamuna A, Mary S, Ping Z. Cost-effectiveness of the interventions. Diabetes Care. 2007;30(10):2548–52.
86. Floyd K, Arora VK, Murthy KJR, Lonnroth K, Singla N, Akbar Y, et al. Cost and cost-effectiveness of PPM-DOTS for tuberculosis control:
evidence from India. Bull World Health Organ. 2006;84(05):437–45.
87. Kumar M, Birch S, Maturana A, Gafni A. Economic evaluation of HIV screening in pregnant women attending antenatal clinics in India.
Health Policy (N Y). 2006;77(2):233–43.
88. Over M, Marseille E, Sudhakar K, Gold J, Gupta I, Indrayan A, et al. Antiretroviral therapy and HIV prevention in India: modeling
costs and consequences of policy options. Sex Transm Dis. 2006;33(10):S145–52.
89. Shafiq N, Malhotra S, Pandhi P, Sharma N, Bhalla A, Grover A. A randomized controlled clinical trial to evaluate the efficacy,
safety, cost-effectiveness and effect on PAI-1 levels of the three low-molecular-weight heparins - Enoxaparin, nadroparin and
dalteparin: the ESCAPe-END study. Pharmacology. 2006;78(3):136–43.
90. Sood S, Nambiar D. Comparative cost-effectiveness of the components of a behavior change communication campaign on HIV/AIDS in
North India. J Health Commun. 2006;11(Suppl 2):143–62.
91. Suraratdecha C, Jacobson J, Sivalenka S, Narahari D.A cost-effectiveness analysis of strategies for controlling Japanese
encephalitis in Andhra Pradesh, India.J Pharm Financ Econ Policy. 2006;15(1):21–40.
92. Goldie SJ, Gaffikin L, Goldhaber-Fiebert JD, Gordillo-Tobar A, Levin C, Mahé C, et al. Cost-effectiveness of cervical-cancer
screening in five developing countries. N Engl J Med. 2005;353(20):2158–68.
93. Legood R, Gray AM, Mahé C, Wolstenholme J, Jayant K, Nene BM, et al. Screening for cervical cancer in India: How much will it cost?
A trial based analysis of the cost per case detected. Int J Cancer. 2005;117(6):981–7.
94. Bhatia MR, Fox-Rushby J, Mills A. Cost-effectiveness of malaria control interventions when malaria mortality is low:
Insecticide-treated nets versus in-house residual spraying in India. SocSci Med. 2004;59(3):525–39.
95. Poulos C, Bahl R, Whittington D, Bhan MK, Clemens JD, Acosta CJ. A cost-benefit analysis of typhoid fever immunization programs
in an Indian urban slum community. J Health PopulNutr. 2004;22(3):311–21.
96. Sahni M, Jindal K, Abraham M, Aruldas K, Puliyel JM. Hepatitis B Immunization: cost calculation in a community based study in India.
Indian J Gastroenterol. 2004;23(1):16–8.
97. Aggarwal R, Ghoshal UC, Naik SR. Assessment of
cost effectiveness of universal hepatitis B immunization in a low income country with intermediate endimicity using a Markov model. J Hepatol. 2003;38(2):215–22.
98. Ghoshal UC, Aggarwal R, Baba CS. Recurrent duodenal ulcer haemorrhage: a pharmacoeconomic comparison of various management
strategies. Expert OpinPharmacother. 2003;4:1593–603.
99. Gogtay NJ, Kadam VS, Desai S, Kamtekar KD, Dalvi SS, Kshirsagar NA.A cost-effectiveness analysis of three antimalarial treatments
for acute, uncomplicated Plasmodium falciparum malaria in Mumbai. India. J Assoc Physicians India. 2003;51:877–9.
100. Patel AB, Dhande LA, Rawat MS. Economic evaluation of zinc and copper use in treating acute diarrhea in children: a randomized
controlled trial. Cost EffResourAlloc. 2003;1(1):7.
101. Patel V, Chisholm D, Rabe-Hesketh S, Dias-Saxena F, Andrew G, Mann A. Efficacy and cost-effectiveness of drug and psychological
treatments for common mental disorders in general health care in Goa, India: A randomised, controlled trial.
102. Prakash C. Crucial factors that influence cost effectiveness of Universal Hepatitis B immunization in India. Int J Technol Assess
Health Care. 2003;19(1):28–40.
103. Krishnamoorthy K, Rajendran R, Sunish IP, Reuben R. Cost effectiveness of the use of vectrol control and mass drug administration,
seperately or in combination, against lymphatic filariasis. Ann Trop Med Parasitol. 2002;96:S77–90.
104. Aggarwal R, Ghoshal UC, Naik SR. Treatment of Chronic hepatitis B with interferon-alpha: Cost-effectiveness in developing countries.
Natl Med J India. 2002;15(6):320–7.
105. Ghoshal UC, Aggarwal R, Kumar S, Naik SR. Pneumatic dilation versus intrasphinctericbotulinum toxin injection in the treatment of
achalasia cardia in India: an economic analysis. Indian J Gastroenterol. 2002;21(5):193–6.
106. Srivastava A, Srinivas G, Misra MC, Pandav CS, Seenu V, Goyal A. Cost-effectiveness analysis of laparoscopic versus minilaparotomy
cholecystectomy for gallstone disease. A randomized trial.Int J Technol Assess Health Care. 2001;17(4):497–502.
107. Subramaniam B, Madan R, Sadhasivam S, Sennaraj B, Tamilselvan P, Rajeshwari S, et al. Dexamethasone is a cost-effective alternative
to ondansertron in preventing PONV after paediatric strabismur repair. Br J Anaesth. 2001;86(1):84–9.
108. Singh A J, Garner P, Floyd K. Cost-effectiveness of public-funded options for cataract surgery in Mysore, India.Lancet.
109. Awasthi S, Pande VK, Fletcher RH. Effectiveness and cost-effectiveness of albendazole in improving nutritional status of pre-school
children in urban slums.Indian Pediatr. 2000;37(1):19–29.
110. Miller MA, Kane M. Routine hepatitis B immunisation in India: cost-effectiveness assessment. Indian J Pediatr. 2000;67(4):299–300.
111. Bhatia SJ, Kulkarni SG. Cost-effectiveness of Helicobacter pylori eradication in India: to live and let live … expensively?
Indian J Gastroenterol. 1997;16(Suppl 1):S25–8.
112. Thomas K, Peter JV, Cherian AM, Guyatt G. Cost-effectiveness of inhaled β-agonists v. oral salbutamol in asthma: A randomized
double-blind cross-over study. Natl Med J India. 1996;9(4):159–62.
113. McNeil BJ, Dudley RA, Hoop B, Metz C, Thompson M, Adelstein SJ.A cost-effectiveness analysis of screening for hepatitis B surface
antigen in India.Med Decis Making. 1981;1(4):345–59.
114. McNeil BJ, Thompson M, Adelstein SJ. Cost effectiveness calculations for the diagnosis and treatment of tuberculous meningitis.
Eur J Nucl Med. 1980;5(3):271–6.
115. Isaac MK, Kapur R. A cost-effectiveness analysis of three different methods of psychiatric case finding in the general population.
Br J Psychiatry. 1980;137(6):540–6.